Related Experiment Videos

Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys

Annals of Neurology
|October 1, 1986
PubMed

Insights

Systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes parkinsonism. New findings reveal MPTP also damages the locus ceruleus and forms inclusion bodies in monkeys, mirroring human Parkinson's disease pathology.

Area of Science:

  • Neuroscience
  • Toxicology
  • Neuropathology

Background:

  • 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin causing parkinsonism.
  • Previous research indicated MPTP primarily affects the substantia nigra, with limited extranigral damage in primates.

Purpose of the Study:

  • To investigate the extranigral neuropathological effects of a protracted MPTP regimen in older squirrel monkeys.
  • To compare MPTP-induced lesions with neuropathological hallmarks of human Parkinson's disease.

Main Methods:

  • Squirrel monkeys received a protracted regimen of MPTP.
  • Histopathological examination focused on extranigral brain regions, particularly the locus ceruleus.
  • Inclusion bodies were characterized and compared to Lewy bodies in human Parkinson's disease.

Main Results:

  • Protracted MPTP administration induced lesions in the locus ceruleus of squirrel monkeys.
  • Eosinophilic inclusion bodies, similar to Lewy bodies, were observed in MPTP-treated animals.
  • No such neuropathological abnormalities were found in control animals.

Conclusions:

  • MPTP-induced parkinsonism in monkeys exhibits greater neuropathological similarity to human Parkinson's disease than previously recognized.
  • The findings enhance the utility of the MPTP monkey model for studying Parkinson's disease mechanisms and potential therapies.

Related Concept Videos